← Back to Clinical Trials
Recruiting NCT06791473

NCT06791473 AI-Driven Cancer Diagnosis and Prediction With EHR

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06791473
Status Recruiting
Phase
Sponsor The Eye Hospital of Wenzhou Medical University
Condition Tumor
Study Type OBSERVATIONAL
Enrollment 1,000,000 participants
Start Date 2025-01-19
Primary Completion 2025-10-01

Eligibility & Interventions

Sex All sexes
Min Age 0 Years
Max Age 90 Years
Study Type OBSERVATIONAL
Interventions
AI-Based Diagnostic and Prognostic Model

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,000,000 participants in total. It began in 2025-01-19 with a primary completion date of 2025-10-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a multi-center, clinical study designed to evaluate the application and effectiveness of an AI-assisted predictive model for identifying and diagnosing cancer, leveraging multimodal health data.

Eligibility Criteria

Inclusion Criteria: 1、Patients with comprehensive electronic health records (EHRs), including medical history, laboratory test results, imaging data, and genetic data (if available). 2\. Individuals without severe cognitive impairments or conditions that would prevent them from providing informed consent or participating in the study. 3\. Parents or guardians must provide informed consent for minors, while adult participants must provide informed consent for themselves. Exclusion Criteria: 1. Patients with incomplete or missing key electronic health record data or insufficient follow-up data. 2. Individuals with severe cognitive disorders or other terminal illnesses that would prevent meaningful participation. 3. Pregnant women (although pediatric cancers are being considered, pregnant women would be excluded for safety reasons).

Contact & Investigator

Central Contact

Fei Liu, MD

✉ liufei_2359@163.com

📞 +86 13810512704

Frequently Asked Questions

Who can join the NCT06791473 clinical trial?

This trial is open to participants of all sexes, aged 0 Years or older, up to 90 Years, studying Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06791473 currently recruiting?

Yes, NCT06791473 is actively recruiting participants. Contact the research team at liufei_2359@163.com for enrollment information.

Where is the NCT06791473 trial being conducted?

This trial is being conducted at Guangzhou, China, Guangzhou, China, Guangzhou, China, Guangzhou, China and 3 additional locations.

Who is sponsoring the NCT06791473 clinical trial?

NCT06791473 is sponsored by The Eye Hospital of Wenzhou Medical University. The trial plans to enroll 1,000,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology